BSE Sensex 30 Stocks Regulatory Filings — October 12, 2026

12-10-2026

HCL Technologies' Board approved unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026, and declared an Interim Dividend of Rs. 12 per equity share (face value Rs. 2) for FY 2026-27, with a record date of October 16, 2026 and payment date of October 26, 2026. The filing contains only a cover letter and auditor limited review reports; the actual revenue, profit, and segment figures are not reproduced in the text provided, so no period-over-period performance comparison can be made from this document.

• · Record date for interim dividend is October 16, 2026; payment date is October 26, 2026
• · Board meeting commenced 1:00 PM IST and concluded 4:00 PM IST on October 12, 2026
• · Auditor issued a limited review (not audit) conclusion with no material misstatement identified on both consolidated and standalone results
• · Consolidated results cover 131 entities, including new subsidiaries and an associate (Axonwise Private Limited, effective 25 June 2026)
• · Recent corporate restructuring: an AI-focused subsidiary (HCLTech AI Platforms Limited) and an SPV (HCLTech AI Platforms SPV Limited) were incorporated in July and September 2026, respectively

12-10-2026

HCLTech announced a Global Premier Partnership with Anthropic to accelerate enterprise adoption of governed Agentic AI, including a dedicated Anthropic Business Unit and Centre of Excellence and HCLSoftware becoming an Anthropic ISV partner to embed Claude into select products such as HCL BigFix and HCL AppScan. The filing is a press release with no disclosed financial impact, deal value, or revenue guidance.

• · HCLSoftware will embed Claude capabilities into cybersecurity, automation, business process and application development products
• · Claude and Claude Code will be integrated into AIForce across IT support, code remediation and digital employee services, with policy guardrails and human oversight for high-impact changes
• · HCLTech will provide secure sandbox environments for enterprise Claude deployments through forward-deployed engineers (FDEs)
• · Consolidated revenues for the 12 months ending June 2026 were $14.8 billion

12-10-2026

HCL Technologies' Board approved the un-audited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026, with statutory auditor BSR & Co. LLP issuing unmodified limited review reports. The Board also declared an interim dividend of Rs. 12 per equity share of Rs. 2 face value for FY 2026-27, with a record date of October 16, 2026 and payment date of October 26, 2026. The filing itself does not disclose revenue, profit, or EPS figures in the content provided, so the headline financial metrics cannot be verified from this document.

• · Interim dividend record date: October 16, 2026; payment date: October 26, 2026
• · Board meeting ran from 1:00 PM to 4:00 PM IST on October 12, 2026
• · Limited review reports (consolidated and standalone) state nothing came to attention indicating material misstatement
• · Consolidated results cover 131 entities, including recent additions: HCLTech Engineering and AI Solutions Private Limited (acquired July 31, 2026), HCLTech AI Platforms Limited (incorporated July 31, 2026), HCLTech AI Platforms SPV Limited (incorporated September 28, 2026), and Axonwise Private Limited as an associate (from June 25, 2026)
• · The review report notes the associate's share of net loss after tax and total comprehensive loss for the period

12-10-2026

HCL Technologies' Board approved the un-audited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026, and declared an Interim Dividend of Rs. 12 per equity share (face value Rs. 2) for FY 2026-27, with a record date of October 16, 2026 and payment date of October 26, 2026. The filing attaches limited review reports from B S R & Co. LLP, which found nothing requiring modification. The results statements themselves are not reproduced in the content provided, so no revenue, profit, or EPS figures can be verified from this filing.

• · Board meeting ran from 01:00 PM to 4:00 PM (IST) on October 12, 2026.
• · Auditor's limited reviews (consolidated and standalone) cover 131 consolidated entities, including one associate (Axonwise Private Limited, from June 25, 2026), and report no material misstatement.
• · Newly acquired or incorporated entities include HCLTech Engineering and AI Solutions Private Limited (acquired July 31, 2026) and HCLTech AI Platforms Limited (incorporated July 31, 2026), plus HCLTech AI Platforms SPV Limited (incorporated September 28, 2026).

12-10-2026

HCL Technologies reported Q2 FY27 (quarter ended September 30, 2026) revenue of ₹35,620 Crore, up 3.0% QoQ and 11.5% YoY, with EBIT margin of 18.2% (including 84 bps restructuring cost) and Net Income of ₹5,132 Crore, up 11.0% QoQ and 21.2% YoY. Advanced AI Services revenue grew 28.4% QoQ and 78.0% YoY in constant currency, but HCLSoftware revenue declined 11.2% YoY in constant currency and 5.8% QoQ, and Europe revenue declined 0.3% YoY in CC, so performance is mixed across segments and geographies.

• · Total bookings of $3,258M (up 27% YoY) with first-half bookings at a record high
• · HCLSoftware ARR grew 7.8% YoY in CC to ₹1,134 (reported as 1,134)
• · Retail & CPG vertical grew 14.0% YoY CC; Financial Services grew 7.1% YoY CC
• · Lifesciences & Healthcare (-2.1%) and Telecommunications, Media, Publishing & Entertainment (-2.1%) declined YoY in CC
• · HCLSoftware EBIT margin fell 636 bps YoY to 20.1%; Engineering & R&D EBIT margin declined 231 bps YoY to 15.2%
• · Client concentration: Top 10 clients contributed 18.4% of LTM revenue, down from 19.9% a year ago
• · Attrition (LTM) rose to 12.8% from 12.6% a year ago; R&D expense rose to 1.9% of revenue from 1.5%
• · FY27 guidance: revenue growth 2.5%-4.0% in CC; EBIT margin 17.5%-18.5%; dividend per share ₹12 for the period

12-10-2026

HCL Technologies released its condensed consolidated interim IFRS financial statements for the three and six months ended 30 September 2026, with revenue rising 2.2% YoY to $3,724 million in Q2 and 2.6% YoY to $7,374 million for H1. Profit for the period grew 10.7% YoY to $538 million in the quarter and 9.6% to $1,026 million for the half, though Q2 operating profit growth was modest at 6.3% and other income fell sharply, with other income (expenses), net down 42.9% YoY to $24 million in Q2 and 34.7% to $62 million for H1.

• · Net cash from operating activities fell 26.7% to $815 million in H1 FY27 from $1,112 million in H1 FY26, driven by a $675 million build in other financial and other assets.
• · Other bank balances declined to $1,081 million from $1,599 million at 31 March 2026, and current investments fell to $308 million from $734 million.
• · Other current assets rose sharply to $1,250 million from $581 million at 31 March 2026, a significant balance-sheet movement.
• · Other current liabilities increased to $838 million from $244 million at 31 March 2026.
• · Foreign currency translation reserve movements weighed on OCI, with Q2 translation loss of $44 million versus a $124 million loss in Q2 FY26.
• · Share of loss of an associate of $4 million was recorded in both Q2 and H1 FY27, following $151 million invested in an associate during H1.
• · Income tax expense fell 17.3% YoY in Q2 to $139 million, while H1 income tax fell 8.9% to $296 million.

12-10-2026

UltraTech Cement Limited announced that shareholders passed, via postal ballot (remote e-voting closing 11 October 2026), an ordinary resolution re-appointing Mr. Vivek Agrawal (DIN: 10599212) as Whole-time Director and Chief Marketing Officer. The resolution was approved with 99.13% of votes polled in favour, though 0.87% of votes polled were cast against, with the Public-Institutions and Public-Non Institutions categories showing dissent of 2.51% and 0.09% respectively.

• · Promoter and Promoter Group voted 100% in favour of the resolution, while Public-Institutions cast 2.51% of their votes against.
• · Public-Institutions participation was approximately 88.6 million shares voted out of 97.4 million outstanding (about 90.95%), and Public-Non Institutions participation was only about 6.41% of their outstanding shares.
• · Resolution is an ordinary resolution under SEBI Listing Regulations (Regulations 30 and 44), with the Scrutinizer's report dated 12 October 2026 and voting results to be posted on the company website.

12-10-2026

ICICI Bank Limited has scheduled a media call at 4:00 p.m. IST and an analyst/investor earnings call at 5:00 p.m. IST on October 17, 2026, to discuss its financial results for the quarter and six months ended September 30, 2026. Dial-in details and pre-registration links were provided, and audio recordings and transcripts will be posted on the Bank's website. This is a scheduling notice only; no financial figures were disclosed in the filing.

• · Media call scheduled for 4:00 p.m. IST on October 17, 2026; dial-in details to be shared separately with participants
• · Earnings call scheduled for 5:00 p.m. IST on October 17, 2026, with universal and toll-free dial-in numbers across India, Hong Kong, Singapore, UK, and USA
• · Audio recording and transcript of both calls to be posted at icici.bank.in

12-10-2026

Sun Pharmaceutical Industries Limited's Board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs) on a private placement basis for an aggregate amount not exceeding INR 10,000 Crore, with tranche-specific terms delegated to the Finance Committee. Independent Director Mr. Gautam Doshi (DIN: 00004612) resigned effective 12 October 2026, citing personal reasons and confirming no other material reasons.

• · Finance Committee authorized to determine and approve tranche-specific NCD terms, including issuance, allocation and allotment
• · Regulation 30 disclosures for the NCDs to be made at the appropriate stage upon issuance and/or allotment
• · Board meeting ran from 5:00 PM to 5:50 PM IST on 12 October 2026
• · Mr. Gautam Doshi confirmed no material reasons for resignation beyond those stated in his resignation letter (Annexure B)